Ved transdermal indgivelse af oxybutynin undgås førstepassage- metabolismen i mavetarmkanal og lever, hvilket reducerer dannelsen af N- desethyl- metabolitten.
Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyl metabolite.